Home DNA Damage/DNA Repair DNA/RNA Synthesis inhibitor - Apoptosis related activator - CMV inhibitor Floxuridine (FUDR) For research use only.

Floxuridine (FUDR)

Synonyms: NSC 27640, Deoxyfluorouridine

Floxuridine (FUDR) is a prodrug that is rapidly catabolized to 5-fluorouracil in vivo. Floxuridine is used to treat various cancers, particularly metastases to the liver. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage and apoptosis. Floxuridine has antiviral effects against HSV and CMV.

Floxuridine (FUDR) Chemical Structure

Floxuridine (FUDR) Chemical Structure

CAS No. 50-91-9

Purity & Quality Control

Floxuridine (FUDR) Related Products

Signaling Pathway

DNA/RNA Synthesis Signaling Pathways

DNA/RNA Synthesis Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CCRF-CEM cell Growth inhibition assay Tested in vitro for the inhibition of cell growth of human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119), IC50=0.5 μM 11909716
CCRF-CEM Growth inhibition assay In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL), GI50=0.0006 μM 11597404
LNCaP cells Cytotoxicity assay Cytotoxic concentration in prostate specific antigen (PSA) producing human LNCaP cells, IC50=0.0692 μM 12161157
TSU cells Cytotoxicity assay Cytotoxic concentration in non prostate specific antigen (PSA) producing human TSU cells, IC50=0.058 μM 12161157
KBALB cell Cytotoxicity assay In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line), CC50=6.00E-05 μM 12620076
KBALB-STK cell Cytotoxicity assay In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK, IC50=8.80E-05 μM 12620076
L1210 mouse leukemia cells Growth inhibition assay 24 h Growth inhibition in L1210 mouse leukemia cells after 24 h treatment, IC50=0.0041 μM 11728193
L1210 mouse leukemia cells Growth inhibition assay 48 h Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment, IC50=0.00064 μM 11728193
L5178Y cell Growth inhibition assay Comparative inhibition of L5178Y cell growth in vitro (concentration required for 50% inhibition), IC50=0.00076 μM 6779007
L5178Y cells Function assay Inhibitory concentration of compound was calculated on L5178Y cells by [14C]Leu incorporation, IC50=2 μM 8246229
L1210 mouse leukemia cells Function assay 2 h Thymidylate synthase inhibition in L1210 mouse leukemia cells after 2 hr treatment, IC50=0.0079 μM 11728193
LM cells Function assay 2 h Thymidylate synthase inhibition in thymidine kinase deficient LM cells after 2 hr treatment, IC50=5.4 μM 11728193
HT1080 cells Function assay Cytostatic activity against human HT1080 cells by MTT assay, IC50=0.18 μM 17804231
L1210 cells Growth inhibition assay 72 h Cytostatic activity against mouse L1210 cells ATCC CCL219 assessed as growth reduction after 72 hrs, IC50=0.012 μM 17997319
HL60 cells Growth inhibition assay 72 h Cytostatic activity against human HL60 cells ATCC CCL 240 assessed as growth reduction after 72 hrs, IC50=0.012 μM 17997319
CCRF-CEM cells Growth inhibition assay 72 h Cytostatic activity against human CCRF-CEM cells ATCC CCL 119 assessed as growth reduction after 72 hrs, IC50=0.017 μM 17997319
L1210 cells Growth inhibition assay 72 h Cytostatic activity in mouse L1210 cells assessed as inhibition of cell growth after 72 hrs, IC50=0.012 μM 18078757
HL60 cells Growth inhibition assay 72 h Cytostatic activity in human HL60 cells assessed as inhibition of cell growth after 72 hrs, IC50=0.012 μM 18078757
CCRF-CEM cells Growth inhibition assay 72 h Cytostatic activity in human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs, IC50=0.017 μM 18078757
CCRF-CEM cells Function assay 48 h Anticancer activity against human CCRF-CEM cells after 48 hrs by sulforhodamine B assay, GI50=0.00631 μM 19744858
K562 cells Function assay 48 h Anticancer activity against human K562 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM 19744858
MOLT4 cells Function assay 48 h Anticancer activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM 19744858
RPMI8266 cells Function assay 48 h Anticancer activity against human RPMI8266 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM 19744858
human SR cells Function assay 48 h Anticancer activity against human SR cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM 19744858
A549 cells Function assay 48 h Anticancer activity against human A549 cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM 19744858
EKVX cells Function assay 48 h Anticancer activity against human EKVX cells after 48 hrs by sulforhodamine B assay, GI50=10 μM 19744858
HOP62 cells Function assay 48 h Anticancer activity against human HOP62 cells after 48 hrs by sulforhodamine B assay, GI50=0.02512 μM 19744858
HOP92 cells Function assay 48 h Anticancer activity against human HOP92 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM 19744858
NCI-H226 cells Function assay 48 h Anticancer activity against human NCI-H226 cells after 48 hrs by sulforhodamine B assay 19744858
NCI-H23 Function assay 48 h Anticancer activity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM 19744858
NCI-H322 Function assay 48 h Anticancer activity against human NCI-H322M cells after 48 hrs by sulforhodamine B assay, GI50=0.50119 μM 19744858
NCI-H460 Function assay 48 h Anticancer activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay, GI50=0.50119 μM 19744858
NCI-H522 Function assay 48 h Anticancer activity against human NCI-H522 cells after 48 hrs by sulforhodamine B assay, GI50=0.002 μM 19744858
COLO205 cells Function assay 48 h Anticancer activity against human COLO205 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM 19744858
HCC2998 cells Function assay 48 h Anticancer activity against human HCC2998 cells after 48 hrs by sulforhodamine B assay, GI50=1.58489 μM 19744858
HCT116 cells Function assay 48 h Anticancer activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50=0.001 μM 19744858
HCT15 cells Function assay 48 h Anticancer activity against human HCT15 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM 19744858
HT-29 cells Function assay 48 h Anticancer activity against human HT-29 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM 19744858
KM12 cells Function assay 48 h Anticancer activity against human KM12 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM 19744858
SW620 cells Function assay 48 h Anticancer activity against human SW620 cells after 48 hrs by sulforhodamine B assay, GI50=6.30957 μM 19744858
SF268 cells Function assay 48 h Anticancer activity against human SF268 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM 19744858
SF295 cells Function assay 48 h Anticancer activity against human SF295 cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM 19744858
SF539 cells Function assay 48 h Anticancer activity against human SF539 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM 19744858
SNB19 cells Function assay 48 h Anticancer activity against human SNB19 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM 19744858
SNB75 cells Function assay 48 h Anticancer activity against human SNB75 cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM 19744858
U251 cells Function assay 48 h Anticancer activity against human U251 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM 19744858
LOXIMVI cells Function assay 48 h Anticancer activity against human LOXIMVI cells after 48 hrs by sulforhodamine B assay, GI50=0.02512 μM 19744858
MALME-3M cells Function assay 48 h Anticancer activity against human MALME-3M cells after 48 hrs by sulforhodamine B assay, GI50=7.94328 μM 19744858
M14 cells Function assay 48 h Anticancer activity against human M14 cells after 48 hrs by sulforhodamine B assay, GI50=0.15849 μM 19744858
SK-MEL-2 cells Function assay 48 h Anticancer activity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM 19744858
SK-MEL-28 cells Function assay 48 h Anticancer activity against human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM 19744858
SK-MEL-5 cells Function assay 48 h Anticancer activity against human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM 19744858
UACC257 cells Function assay 48 h Anticancer activity against human UACC257 cells after 48 hrs by sulforhodamine B assay, GI50=3.16228 μM 19744858
UACC62 cells Function assay 48 h Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM 19744858
IGROV1 cells Function assay 48 h Anticancer activity against human IGROV1 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM 19744858
OVCAR-3 cells Function assay 48 h Anticancer activity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM 19744858
OVCAR4 cells Function assay 48 h Anticancer activity against human OVCAR4 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM 19744858
OVCAR5 cells Function assay 48 h Anticancer activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay, GI50=6.30957 Μm 19744858
OVCAR8 cells Function assay 48 h Anticancer activity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM 19744858
SKOV3 cells Function assay 48 h Anticancer activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM 19744858
786-0 cells Function assay 48 h Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay, GI50=0.1 μM 19744858
A498 cells Function assay 48 h Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM 19744858
ACHN cells Function assay 48 h Anticancer activity against human ACHN cells after 48 hrs by sulforhodamine B assay, GI50=0.03162 μM 19744858
Caki1 cells Function assay 48 h Anticancer activity against human Caki1 cells after 48 hrs by sulforhodamine B assay, GI50=0.03162 μM 19744858
SN12C cells Function assay 48 h Anticancer activity against human SN12C cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM 19744858
TK10 cells Function assay 48 h Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay, GI50=5.01187 μM 19744858
UO31 cells Function assay 48 h Anticancer activity against human UO31 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM 19744858
PC3 cells Function assay 48 h Anticancer activity against human PC3 cells after 48 hrs by sulforhodamine B assay, GI50=0.31623 μM 19744858
DU145 cells Function assay 48 h Anticancer activity against human DU145 cells after 48 hrs by sulforhodamine B assay, GI50=0.25119 μM 19744858
MCF7 cells Function assay 48 h Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay, GI50=0.00631 μM 19744858
NCI/ADR-RES cells Function assay 48 h Anticancer activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM 19744858
MDA-MB-231 cells Function assay 48 h Anticancer activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM 19744858
Hs 578T cells Function assay 48 h Anticancer activity against human Hs 578T cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM 19744858
MDA-MB-435 cells Function assay 48 h Anticancer activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay, GI50=3.16228 μM 19744858
MDA-N cells Function assay 48 h Anticancer activity against human MDA-N cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM 19744858
BT549 cells Function assay 48 h Anticancer activity against human BT549 cells after 48 hrs by sulforhodamine B assay, GI50=1 μM 19744858
T47D cells Function assay 48 h Anticancer activity against human T47D cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM 19744858
HepG2 cells Cytotoxicity assay 72 h Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, EC50=18.84 μM 19917528
A549 cells Cytotoxicity assay 72 h Cytotoxicity against human A549 cells after 72 hrs by MTT assay, EC50=9.74 μM 19917528
LAC cells Cytotoxicity assay 72 h Cytotoxicity against human LAC cells after 72 hrs by MTT assay, EC50=32.09 μM 19917528
HeLa cells Cytotoxicity assay 72 h Cytotoxicity against human HeLa cells after 72 hrs by MTT assay, EC50=10.26 μM 19917528
MDA-MB-231 cells Cytotoxicity assay Cytotoxicity against human MDA-MB-231 cells overexpressing urokinase plasminogen activator, IC50=0.21 μM 20363130
human ACHN cells Function assay Anticancer activity against human ACHN cells by SRB assay, GI50=2.1 μM 20732810
PC3 cells Function assay Anticancer activity against human PC3 cells by SRB assay, GI50=4.97 μM 20732810
MDA-MB-231 cells Function assay Anticancer activity against human MDA-MB-231 cells by SRB assay, GI50=0.16 μM 20732810
FM3A cells Function assay 2 days Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis, IC50=0.0094 μM 21330014
HeLa cells Function assay Cytostatic activity against human HeLa cells in presence of 20 uM thymidine, IC50=8.5 μM 21330014
LLC cells Cytotoxicity assay 24 h Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay, IC50=14.2 μM 21536448
LLC cells Cytotoxicity assay 72 h Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay, IC50=2 μM 21536448
RAW264.7 cells Cytotoxicity assay 72 h Cytotoxicity against mouse RAW264.7 cells after 72 hrs by resazurin assay, IC50=30 μM 21536448
A549 cells Cytotoxicity assay 72 h Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by WST-8 assay, IC50=0.047 μM 22248856
A2780 cells Cytotoxicity assay 5 days Cytotoxicity against human A2780 cells after 5 days by MTT assay, IC50=0.026 μM 22738636
LMTK cells Cytotoxicity assay 5 days Cytotoxicity against thymidine kinase-deficient mouse LMTK cells after 5 days by MTT assay, IC50=4.5 μM 22738636
A549 cells Cytotoxicity assay 72 h Cytotoxicity against human A549 cells after 72 hrs by microplate reader method, IC50=0.0124 μM 22847019
CEM cells Function assay 72 h Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR, IC50=0.8 μM 21892829
Hela cells Function assay 72 h Cytostatic activity against human HeLa cells after 72 hrs by cell counting, IC50=0.05 μM 21892829
CEM/0 cells Function assay 72 h Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting, IC50=0.022 μM 21892829
L1210/0 cells Function assay 48 h Cytostatic activity against mouse L1210/0 cells after 48 hrs by cell counting, IC50=0.0009 μM 21892829
MCF7 cells Cytotoxicity assay 72 h Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50=12.19 μM 23867603
HeLa cells Cytotoxicity assay 72 h Cytotoxicity against human HeLa cells after 72 hrs by SRB assay, IC50=6.5 μM 23867603
HL60 cells Proliferation assay 72 h Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.24 μM 25644674
SW707 cells Proliferation assay 72 h Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=23.86 μM 25644674
LoVo cells Proliferation assay 72 h Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method, IC50=19.07 μM 25644674
BALB/3T3 cell Proliferation assay 72 h Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=23.9 μM 25644674
HFF cells Function assay 72 h Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay, EC50=0.91 μM 17698618
CCRFCEM cells Function assay Cytostatic activity against human CCRFCEM cells by MTT assay, IC50=0.29 μM 17804231
RXF393 cells Function assay 48 h Anticancer activity against human RXF393 cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM 19744858
HL-60(TB) cells Function assay 48 h Anticancer activity against human HL-60(TB) cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM 19744858
L1210 cells Function assay 15 mins Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting, IC50=0.0006 μM 21330014
Colo-357 cells Function assay 100 μM 15 mins Activity at MRP5 in human Colo-357 cells assessed as 5-FdUMP accumulation at 100 uM after 15 mins 20930123
KB cells Cytotoxicity assay 72 h Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50=8.69 μM 23867603
Click to View More Cell Line Experimental Data

Biological Activity

Description Floxuridine (FUDR) is a prodrug that is rapidly catabolized to 5-fluorouracil in vivo. Floxuridine is used to treat various cancers, particularly metastases to the liver. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage and apoptosis. Floxuridine has antiviral effects against HSV and CMV.
In vitro
In vitro Floxuridine exhibits higher affinity for PEPT1 than the corresponding 5'-O-mono amino acid ester prodrugs. [1] Floxuridine combined with Leucovorin results in synergistic inhibitory effects on growth of human T-lymphoblast leukemia cells. [2] Floxuridine significantly inhibits the uptake of both [(3)H]-inosine and [(3)H]-adenosine (60-70% of control), while its amino acid ester prodrugs including Val, Phe, Pro, Asp, and Lys esters exhibits markedly decreased inhibition potency (10-30% of control). [3] Floxuridine inhibits cell proliferation by more than 50% relative to the untreated control cells at 36 days, the cell numbers still increases fourfold compared with the initial cell density. Floxuridine results in prolonged effects on the proliferation of human Tenon's capsule fibroblasts in vitro. [4] Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction. [5]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01042691 Completed
Unresectable Colorectal Liver Metastases
David Bartlett|The Pittsburgh Foundation|Sanofi|University of Pittsburgh
 May 2003 Phase 1
NCT00695201 Completed
Colon Cancer|Rectal Cancer
Memorial Sloan Kettering Cancer Center|University of Medicine and Dentistry of New Jersey|Rutgers The State University of New Jersey|Sanofi
 August 2000 Phase 1
  • https://www.pubmed.ncbi.nlm.nih.gov/18652477
  • https://www.pubmed.ncbi.nlm.nih.gov/2950995
  • https://www.pubmed.ncbi.nlm.nih.gov/16462026
  • https://www.pubmed.ncbi.nlm.nih.gov/1386726
  • https://www.pubmed.ncbi.nlm.nih.gov/19383854

Chemical Information & Solubility

Molecular Weight 246.19 Formula

C9H11FN2O5
CAS No. 50-91-9 SDF Download Floxuridine (FUDR) SDF
Smiles C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O
Storage (From the date of receipt)

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Floxuridine (FUDR) | Floxuridine (FUDR) supplier | purchase Floxuridine (FUDR) | Floxuridine (FUDR) cost | Floxuridine (FUDR) manufacturer | order Floxuridine (FUDR) | Floxuridine (FUDR) distributor